2cureX AB (FRA:2QE) Total Stockholders Equity: €-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 2cureX AB Total Stockholders Equity?

2cureX AB FRA:2QE Total Stockholders Equity is €-0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

2cureX AB's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €-0.00 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. 2cureX AB's Book Value per Share for the quarter that ended in Dec. 2025 was €-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. 2cureX AB's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.00.

2cureX AB  (FRA:2QE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

2cureX AB's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.0033250147437157-0)/25.102916
=-0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

2cureX AB's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.0033250147437157
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2cureX AB Total Stockholders Equity Related Terms

2cureX AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for 2cureX AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2cureX AB Total Stockholders Equity Chart

2cureX AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.22 3.87 0.59 0.41 -0.00

2cureX AB Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial 0.59 0.25 0.41 0.06 -0.00
What does a Total Stockholders Equity of €-0.00 Mil mean?
2cureX AB (FRA:2QE) has a Total Stockholders Equity of €-0.00 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for 2cureX AB and its competitors.
Is 2cureX AB's Total Stockholders Equity too high?
2cureX AB's current Total Stockholders Equity is €-0.00 Mil.
How does 2cureX AB's Total Stockholders Equity compare to VRTX and REGN?
2cureX AB's Total Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for 2cureX AB and its competitors. 2cureX AB's current Total Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current Total Stockholders Equity of €-0.00 Mil. The current Total Stockholders Equity is €-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current Total Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

2cureX AB Business Description

Other Exchanges 2CUREX:Sweden
Address Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.